Boston Scientific U.S. Coronary Stent Sales Reach $86 Mil. In Third Quarter
This article was originally published in The Gray Sheet
Executive Summary
U.S. coronary stent sales by Boston Scientific reached $86 mil. in the third quarter, the firm reported Nov. 12, reflecting its entry into the U.S. stent market with the launch of its NIR-On-Ranger stent system and Radius self expanding stent in mid-August and mid-July, respectively.